The markets opened modestly higher with the Dow adding 7 points to 12,774 after Greek voters chose to stay in the euro. Nasdaq climbed 17 points to 2890.

On the upside

Morgan Stanley analyst Scott Devitt upgraded Groupon (Nasdaq: GRPN) to an overweight rating.

According to TheStreet’s FDA Drug Approval Contest, Arena Pharmaceuticals’ (Nasdaq: ARNA) Lorcaserin is expected to receive regulatory approval on June 27.

Bargain hunters lifted shares of A123 Systems (Nasdaq: AONE).

On the downside

Body Central (Nasdaq: BODY) cut its second quarter and full year earnings and revenue outlook due to weak sales.

DSW (NYSE: DSW) cut its second quarter outlook.

The Food and Drug Administration affirmed its approval for K-V Pharmaceutical’s (NYSE: KVA) preterm birth treatment Makena.

In the broad market, advancing issues outpaced decliners by a margin of nearly 10 to 9 on the NYSE while decliners edged out advancers by 10 to 9 on Nasdaq. The Russell 2000 which tracks small cap stocks climbed held steady at 771.